Researchers from Immunome Inc. and Zentalis Pharmaceuticals Inc. presented preclinical data for IM-1021, a novel tyrosine kinase-like orphan receptor 1 (ROR1)-targeted antibody-drug conjugate with a new topoisomerase 1 (TOP1) linker payload, being developed for the treatment of solid tumors and B-cell malignancies.
Ottimo Pharma Ltd. has emerged from stealth with a focus on developing innovative cancer therapies for solid tumors. The company’s lead program is jankistomig, a PD-1/VEGFR-2 bifunctional antibody.
Cancer Research UK and Kisoji Biotechnology Inc. have signed an agreement to bring Kisoji's naked anti-TROP2 antibody, KJ-103, into a first-in-human trial. KJ-103 is a single domain antibody that binds to a unique epitope on TROP2.
The combination of radiotherapy with immune checkpoint blockade shows promise for synergistic cancer therapy efficacy. LNC-1004 is a vector targeting fibroblast activation protein (FAP) conjugated with Evans Blue for enhanced tumor uptake and retention. Xiamen University and the National University of Singapore have presented data regarding the [177Lu]LNC-1004 radiopharmaceutical in combination with anti-PD-L1 therapy for the treatment of pan-cancers.
Cellbion Co. Ltd. debuted on the tech-heavy Kosdaq board of the Korea Exchange Oct. 16, with share prices closing upward at ₩20,650 (US$14.94) – outdoing its initial price of ₩15,000 per share for 1.9 million shares.
Adcentrx Therapeutics Inc. has received FDA clearance of its IND application for ADRX-0405 for the treatment of select advanced solid tumors. A first-in-human phase Ia/b trial of ADRX-0405 in patients with select advanced solid tumors, including metastatic castration-resistant prostate cancer, will begin enrollment and dosing this quarter.
The anti-HER2 biparatopic antibody (bpAb) KJ-015 was rationally designed at Shanghai Bao Pharmaceuticals Co. Ltd. by leveraging published antibody-antigen structures to share common light chain with two Fab arms, resulting in functionally balanced high affinity for two HER2 nonoverlapping epitopes.
Poseida Therapeutics Inc. has announced the nomination of a new development candidate under its collaboration with F. Hoffmann-La Roche Ltd., triggering a milestone payment from Roche to Poseida.
Chimeric antigen receptor (CAR) T-cell therapies (CAR T) have proven effective in several hematological cancers and are advancing across the pipelines of other types of tumors with limited efficacy, such as in the more complex environment of solid tumors.
RSS
